

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT2/21 - Direct Antiglobulin Test

Deadline: 19.11.2021

Key: >>> ... marks correct (expected) result
> ... marks conditionally correct (acceptable) result
± ... marks the result not evaluated

N ... number of the results
Nrel ... relative number of the results

Test

Sample	Group	N	Result	N _{rel}
(1001) DAT (direct Coombs test)				
1	(14) Bio-Rad	>	4 Positive (1+)	4,7 %
		>>>	34 Positive (2+)	40 %
		>	8 Positive (3+)	9,4 %
	(17) Biogema	>	1 Positive (1+)	1,2 %
	(40) Ortho Clinical Diagnostics	>>>	1 Positive (2+)	1,2 %
		>	3 Positive (3+)	3,5 %
	(80) DiaMed	>	2 Positive (1+)	2,4 %
		>>>	6 Positive (2+)	7,1 %
		>	2 Positive (3+)	2,4 %
		>	1 Positive (4+)	1,2 %
	(159) Grifols	>	3 Positive (1+)	3,5 %
		>>>	14 Positive (2+)	16 %
		>	4 Positive (3+)	4,7 %
		>	1 Positive (4+)	1,2 %
	(173) Sanguin	>	1 Positive (1+)	1,2 %
	----- Total per sample: n = 85 ----- Success: 100 % -----			
2	(14) Bio-Rad	>	3 Positive (2+)	3,5 %
		>>>	36 Positive (3+)	42 %
		>	7 Positive (4+)	8,2 %
	(17) Biogema	>	1 Positive (1+)	1,2 %
	(40) Ortho Clinical Diagnostics	>>>	3 Positive (3+)	3,5 %
		>	1 Positive (4+)	1,2 %
	(80) DiaMed	>	2 Positive (2+)	2,4 %
		>>>	6 Positive (3+)	7,1 %
		>	3 Positive (4+)	3,5 %
	(159) Grifols	>>>	19 Positive (3+)	22 %
		>	3 Positive (4+)	3,5 %
	(173) Sanguin	>	1 Positive (2+)	1,2 %
	----- Total per sample: n = 85 ----- Success: 100 % -----			
Total success: 100 %				
(1002) Sensitization specificity anti-IgG				
1	(0) not specified	>	1 Positive (3+)	2,5 %
	(14) Bio-Rad	>	2 Positive (1+)	5,0 %
		>>>	19 Positive (2+)	48 %
		>	2 Positive (3+)	5,0 %
	(80) DiaMed	>	2 Positive (1+)	5,0 %
		>>>	5 Positive (2+)	13 %
		>	2 Positive (3+)	5,0 %
		>	1 Positive (4+)	2,5 %
	(159) Grifols		1 Negative	2,5 %
		>>>	3 Positive (2+)	7,5 %
		>	1 Positive (3+)	2,5 %
		>	1 Positive (4+)	2,5 %
	----- Total per sample: n = 40 ----- Success: 98 % -----			
2	(0) not specified	>	1 Positive (4+)	2,5 %
	(14) Bio-Rad	>	1 Positive (2+)	2,5 %
		>>>	21 Positive (3+)	53 %
		>	1 Positive (4+)	2,5 %
	(80) DiaMed	>	1 Positive (2+)	2,5 %
		>>>	6 Positive (3+)	15 %
		>	3 Positive (4+)	7,5 %
	(159) Grifols	>>>	5 Positive (3+)	13 %
		>	1 Positive (4+)	2,5 %
	----- Total per sample: n = 40 ----- Success: 100 % -----			
Total success: 98 %				
(1003) Sensitization specificity anti-IgA				
1	(14) Bio-Rad	>>>	22 Negative	71 %
	(80) DiaMed	>>>	9 Negative	29 %
	----- Total per sample: n = 31 ----- Success: 100 % -----			
2	(14) Bio-Rad	>>>	22 Negative	71 %
	(80) DiaMed	>>>	9 Negative	29 %
	----- Total per sample: n = 31 ----- Success: 100 % -----			
Total success: 100 %				

Test	Sample	Group	N	Result	N _{rel}
(1004) Sensitization specificity anti-IgM					
1	(14)	Bio-Rad	>>>	22 Negative	71 %
	(80)	DiaMed	>>>	9 Negative	29 %
-----		Total per sample: n = 31	-----	Success: 100 %	-----
2	(14)	Bio-Rad	>>>	22 Negative	71 %
	(80)	DiaMed	>>>	9 Negative	29 %
-----		Total per sample: n = 31	-----	Success: 100 %	-----
Total success: 100 %					
(1005) Sensitization specificity anti-C3c					
1	(0)	not specified	>>>	1 Negative	3,1 %
	(14)	Bio-Rad	>>>	22 Negative	69 %
	(80)	DiaMed	>>>	9 Negative	28 %
-----		Total per sample: n = 32	-----	Success: 100 %	-----
2	(0)	not specified	>>>	1 Negative	3,1 %
	(14)	Bio-Rad	>>>	22 Negative	69 %
	(80)	DiaMed	>>>	9 Negative	28 %
-----		Total per sample: n = 32	-----	Success: 100 %	-----
Total success: 100 %					
(1006) Sensitization specificity anti-C3d					
1	(14)	Bio-Rad	>>>	23 Negative	64 %
	(80)	DiaMed	>>>	10 Negative	28 %
	(159)	Grifols	>>>	3 Negative	8,3 %
-----		Total per sample: n = 36	-----	Success: 100 %	-----
2	(14)	Bio-Rad	>>>	23 Negative	64 %
	(80)	DiaMed	>>>	10 Negative	28 %
	(159)	Grifols	>>>	3 Negative	8,3 %
-----		Total per sample: n = 36	-----	Success: 100 %	-----
Total success: 100 %					
(1008) Col. agglut: Quantif. IgG-DAT					
1	(14)	Bio-Rad	>	11 1:10	48 %
			>>>	4 1:30	17 %
			>	1 1:300	4,3 %
	(80)	DiaMed	>	3 1:10	13 %
			>>>	4 1:30	17 %
-----		Total per sample: n = 23	-----	Success: 100 %	-----
2	(14)	Bio-Rad	>	10 1:30	43 %
			>>>	5 1:100	22 %
			>	1 1:300	4,3 %
	(80)	DiaMed	>	1 1:30	4,3 %
			>>>	6 1:100	26 %
-----		Total per sample: n = 23	-----	Success: 100 %	-----
Total success: 100 %					
(1009) Col. agglut: Subclass IgG1 1:1					
1	(14)	Bio-Rad	>>>	15 Negative	68 %
	(80)	DiaMed	>>>	7 Negative	32 %
-----		Total per sample: n = 22	-----	Success: 100 %	-----
2	(14)	Bio-Rad	>	8 Negative	36 %
			>>>	5 Positive (1+)	23 %
			>	2 Positive (2+)	9,1 %
	(80)	DiaMed	>	1 Negative	4,5 %
			>>>	5 Positive (1+)	23 %
			>	1 Positive (2+)	4,5 %
-----		Total per sample: n = 22	-----	Success: 100 %	-----
Total success: 100 %					
(1010) Col. agglut: Subclass IgG1 1:100					
1	(14)	Bio-Rad	>>>	14 Negative	67 %
	(80)	DiaMed	>>>	7 Negative	33 %
-----		Total per sample: n = 21	-----	Success: 100 %	-----
2	(14)	Bio-Rad	>>>	14 Negative	67 %
	(80)	DiaMed	>>>	7 Negative	33 %
-----		Total per sample: n = 21	-----	Success: 100 %	-----
Total success: 100 %					
(1011) Col. agglut: Subclass IgG3 1:1					
1	(14)	Bio-Rad	>>>	15 Negative	68 %
	(80)	DiaMed	>>>	7 Negative	32 %
-----		Total per sample: n = 22	-----	Success: 100 %	-----
2	(14)	Bio-Rad	>>>	15 Negative	68 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: PAT2/21 - Direct Antiglobulin Test

Deadline: 19.11.2021

Test	Sample	Group	N	Result	N _{rel}
	2	(80) DiaMed	>>>	7 Negative	32 %
	Total per sample: n = 22		Success: 100 %		
	Total success: 100 %				

(1012) Col. agglut: Subclass IgG3 1:100

1	(14) Bio-Rad	>>>	14	Negative	67 %
	(80) DiaMed	>>>	7	Negative	33 %
	Total per sample: n = 21		Success: 100 %		
2	(14) Bio-Rad	>>>	14	Negative	67 %
	(80) DiaMed	>>>	7	Negative	33 %
	Total per sample: n = 21		Success: 100 %		
	Total success: 100 %				

(1019) AB0 blood group

1	(14) Bio-Rad	>>>	18	Blood group: 0	33 %
	(40) Ortho Clinical Diagnostics	>>>	3	Blood group: 0	5,5 %
	(64) Exbio Olomouc	>>>	1	Blood group: 0	1,8 %
	(80) DiaMed	>>>	2	Blood group: 0	3,6 %
	(159) Grifols	>>>	14	Blood group: 0	25 %
	(172) Immucor	>>>	5	Blood group: 0	9,1 %
	(173) Sanguin	>>>	7	Blood group: 0	13 %
	(174) IVT Imuno	>>>	4	Blood group: 0	7,3 %
	(183) Immunodiagnostic Systems	>>>	1	Blood group: 0	1,8 %
	Total per sample: n = 55		Success: 100 %		
2	(14) Bio-Rad	>>>	18	Blood group: A	33 %
	(40) Ortho Clinical Diagnostics	>>>	3	Blood group: A	5,5 %
	(64) Exbio Olomouc	>>>	1	Blood group: A	1,8 %
	(80) DiaMed	>>>	2	Blood group: A	3,6 %
	(159) Grifols	>>>	14	Blood group: A	25 %
	(172) Immucor	>>>	5	Blood group: A	9,1 %
	(173) Sanguin	>>>	7	Blood group: A	13 %
	(174) IVT Imuno	>>>	4	Blood group: A	7,3 %
	(183) Immunodiagnostic Systems	>>>	1	Blood group: A	1,8 %
	Total per sample: n = 55		Success: 100 %		
	Total success: 100 %				

(1020) Rh D antigen

1	(14) Bio-Rad	>>>	22	Negative (RhD-)	40 %
	(40) Ortho Clinical Diagnostics	>>>	3	Negative (RhD-)	5,5 %
	(52) Dynex	>>>	1	Negative (RhD-)	1,8 %
	(64) Exbio Olomouc	>>>	1	Negative (RhD-)	1,8 %
	(80) DiaMed	>>>	2	Negative (RhD-)	3,6 %
	(159) Grifols	>>>	14	Negative (RhD-)	25 %
	(170) Biotest	>>>	1	Negative (RhD-)	1,8 %
	(172) Immucor	>>>	4	Negative (RhD-)	7,3 %
	(173) Sanguin	>>>	5	Negative (RhD-)	9,1 %
	(174) IVT Imuno	>>>	1	Negative (RhD-)	1,8 %
	(183) Immunodiagnostic Systems	>>>	1	Negative (RhD-)	1,8 %
	Total per sample: n = 55		Success: 100 %		
2	(14) Bio-Rad	>>>	21	Negative (RhD-)	38 %
			1	w/v (RhD weak/variant)	1,8 %
	(40) Ortho Clinical Diagnostics	>>>	3	Negative (RhD-)	5,5 %
	(52) Dynex	>>>	1	Negative (RhD-)	1,8 %
	(64) Exbio Olomouc	>>>	1	Negative (RhD-)	1,8 %
	(80) DiaMed	>>>	2	Negative (RhD-)	3,6 %
	(159) Grifols	>>>	13	Negative (RhD-)	24 %
			1	Positive (RhD+)	1,8 %
	(170) Biotest	>>>	1	Negative (RhD-)	1,8 %
	(172) Immucor	>>>	4	Negative (RhD-)	7,3 %
	(173) Sanguin	>>>	5	Negative (RhD-)	9,1 %
	(174) IVT Imuno	>>>	1	Negative (RhD-)	1,8 %
	(183) Immunodiagnostic Systems	>>>	1	Negative (RhD-)	1,8 %
	Total per sample: n = 55		Success: 96 %		
	Total success: 96 %				

(1021) Antigen C

1	(14) Bio-Rad	>>>	15	Negative	34 %
	(50) Merck	>>>	1	Negative	2,3 %
	(80) DiaMed	>>>	3	Negative	6,8 %
	(159) Grifols	>>>	17	Negative	39 %
	(172) Immucor	>>>	3	Negative	6,8 %

EQA round: PAT2/21 - Direct Antiglobulin Test

Deadline: 19.11.2021

Test	Sample	Group	N	Result	N _{rel}
1	(173) Sanguin	>>>	3	Negative	6,8 %
	(183) Immunodiagnostic Systems	>>>	1	Negative	2,3 %
	(999) another manufacturer	>>>	1	Negative	2,3 %
	Total per sample: n = 44		Success: 100 %	-	
2	(14) Bio-Rad	>>>	15	Negative	34 %
	(50) Merck	>>>	1	Negative	2,3 %
	(80) DiaMed	>>>	3	Negative	6,8 %
	(159) Grifols	>>>	17	Negative	39 %
	(172) Immucor	>>>	3	Negative	6,8 %
	(173) Sanguin	>>>	3	Negative	6,8 %
	(183) Immunodiagnostic Systems	>>>	1	Negative	2,3 %
	(999) another manufacturer	>>>	1	Negative	2,3 %
Total per sample: n = 44		Success: 100 %	-		
Total success: 100 %					
(1022) Antigen c					
1	(14) Bio-Rad	>>>	15	Positive	34 %
	(50) Merck	>>>	1	Positive	2,3 %
	(80) DiaMed	>>>	3	Positive	6,8 %
	(159) Grifols	>>>	17	Positive	39 %
	(172) Immucor	>>>	3	Positive	6,8 %
	(173) Sanguin	>>>	3	Positive	6,8 %
	(183) Immunodiagnostic Systems	>>>	1	Positive	2,3 %
	(999) another manufacturer	>>>	1	Positive	2,3 %
Total per sample: n = 44		Success: 100 %	-		
2	(14) Bio-Rad	>>>	15	Positive	34 %
	(50) Merck	>>>	1	Positive	2,3 %
	(80) DiaMed	>>>	3	Positive	6,8 %
	(159) Grifols	>>>	17	Positive	39 %
	(172) Immucor	>>>	3	Positive	6,8 %
	(173) Sanguin	>>>	3	Positive	6,8 %
	(183) Immunodiagnostic Systems	>>>	1	Positive	2,3 %
	(999) another manufacturer	>>>	1	Positive	2,3 %
Total per sample: n = 44		Success: 100 %	-		
Total success: 100 %					
(1023) Antigen Cw					
1	(14) Bio-Rad	>>>	4	Negative	11 %
	(50) Merck	>>>	1	Negative	2,8 %
	(159) Grifols	>>>	18	Negative	50 %
	(170) Biotest	>>>	1	Negative	2,8 %
	(172) Immucor	>>>	3	Negative	8,3 %
	(173) Sanguin	>>>	7	Negative	19 %
	(174) IVT Imuno	>>>	1	Negative	2,8 %
	(999) another manufacturer	>>>	1	Negative	2,8 %
Total per sample: n = 36		Success: 100 %	-		
2	(14) Bio-Rad	>>>	4	Negative	11 %
	(50) Merck	>>>	1	Negative	2,8 %
	(159) Grifols	>>>	18	Negative	50 %
	(170) Biotest	>>>	1	Negative	2,8 %
	(172) Immucor	>>>	3	Negative	8,3 %
	(173) Sanguin	>>>	7	Negative	19 %
	(174) IVT Imuno	>>>	1	Negative	2,8 %
	(999) another manufacturer	>>>	1	Negative	2,8 %
Total per sample: n = 36		Success: 100 %	-		
Total success: 100 %					
(1024) Antigen E					
1	(14) Bio-Rad	>>>	15	Negative	34 %
	(50) Merck	>>>	1	Negative	2,3 %
	(80) DiaMed	>>>	3	Negative	6,8 %
	(159) Grifols	>>>	17	Negative	39 %
	(172) Immucor	>>>	3	Negative	6,8 %
	(173) Sanguin	>>>	3	Negative	6,8 %
	(183) Immunodiagnostic Systems	>>>	1	Negative	2,3 %
	(999) another manufacturer	>>>	1	Negative	2,3 %
Total per sample: n = 44		Success: 100 %	-		
2	(14) Bio-Rad	>>>	15	Negative	34 %
	(50) Merck	>>>	1	Negative	2,3 %
	(80) DiaMed	>>>	3	Negative	6,8 %

EQA round: PAT2/21 - Direct Antiglobulin Test

Deadline: 19.11.2021

Test	Sample	Group	N	Result	N _{rel}	
2	(159)	Grifols	>>>	17	Negative	39 %
	(172)	Immucor	>>>	3	Negative	6,8 %
	(173)	Sanguin	>>>	3	Negative	6,8 %
	(183)	Immunodiagnostic Systems	>>>	1	Negative	2,3 %
	(999)	another manufacturer	>>>	1	Negative	2,3 %
	Total per sample: n = 44			Success: 100 %		
Total success: 100 %						
(1025) Antigen e						
1	(14)	Bio-Rad	>>>	15	Positive	34 %
	(50)	Merck	>>>	1	Positive	2,3 %
	(80)	DiaMed	>>>	3	Positive	6,8 %
	(159)	Grifols	>>>	17	Positive	39 %
	(172)	Immucor	>>>	3	Positive	6,8 %
	(173)	Sanguin	>>>	3	Positive	6,8 %
	(183)	Immunodiagnostic Systems	>>>	1	Positive	2,3 %
	(999)	another manufacturer	>>>	1	Positive	2,3 %
Total per sample: n = 44			Success: 100 %			
2	(14)	Bio-Rad	>>>	15	Positive	34 %
	(50)	Merck	>>>	1	Positive	2,3 %
	(80)	DiaMed	>>>	3	Positive	6,8 %
	(159)	Grifols	>>>	17	Positive	39 %
	(172)	Immucor	>>>	3	Positive	6,8 %
	(173)	Sanguin	>>>	3	Positive	6,8 %
	(183)	Immunodiagnostic Systems	>>>	1	Positive	2,3 %
	(999)	another manufacturer	>>>	1	Positive	2,3 %
Total per sample: n = 44			Success: 100 %			
Total success: 100 %						
(1026) Antigen K						
1	(14)	Bio-Rad	>>>	15	Negative	33 %
	(50)	Merck	>>>	1	Negative	2,2 %
	(80)	DiaMed	>>>	3	Negative	6,5 %
	(159)	Grifols	>>>	18	Negative	39 %
	(172)	Immucor	>>>	3	Negative	6,5 %
	(173)	Sanguin	>>>	3	Negative	6,5 %
	(174)	IVT Imuno	>>>	1	Negative	2,2 %
	(183)	Immunodiagnostic Systems	>>>	1	Negative	2,2 %
	(999)	another manufacturer	>>>	1	Negative	2,2 %
Total per sample: n = 46			Success: 100 %			
2	(14)	Bio-Rad	>>>	15	Positive	33 %
	(50)	Merck	>>>	1	Positive	2,2 %
	(80)	DiaMed	>>>	3	Positive	6,5 %
	(159)	Grifols	>>>	18	Positive	39 %
	(172)	Immucor	>>>	3	Positive	6,5 %
	(173)	Sanguin	>>>	3	Positive	6,5 %
	(174)	IVT Imuno	>>>	1	Positive	2,2 %
	(183)	Immunodiagnostic Systems	>>>	1	Positive	2,2 %
	(999)	another manufacturer	>>>	1	Positive	2,2 %
Total per sample: n = 46			Success: 100 %			
Total success: 100 %						
(1027) Antigen k						
1	(14)	Bio-Rad	>>>	3	Positive	13 %
	(64)	Exbio Olomouc	>>>	2	Positive	8,7 %
	(80)	DiaMed	>>>	3	Positive	13 %
	(159)	Grifols	>>>	1	Positive	4,3 %
	(172)	Immucor	>>>	1	Positive	4,3 %
	(173)	Sanguin	>>>	13	Positive	57 %
Total per sample: n = 23			Success: 100 %			
2	(14)	Bio-Rad	>>>	3	Positive	13 %
	(64)	Exbio Olomouc	>>>	2	Positive	8,7 %
	(80)	DiaMed	>>>	3	Positive	13 %
	(159)	Grifols	>>>	1	Positive	4,3 %
	(172)	Immucor	>>>	1	Positive	4,3 %
	(173)	Sanguin	>>>	13	Positive	57 %
Total per sample: n = 23			Success: 100 %			
Total success: 100 %						
(1028) Antigen M						
1	(6)	APR	>>>	1	Positive	4,0 %

EQA round: PAT2/21 - Direct Antiglobulin Test

Deadline: 19.11.2021

Test	Sample	Group	N	Result	N _{rel}
1	(14)	Bio-Rad	>>>	3 Positive	12 %
	(64)	Exbio Olomouc	>>>	2 Positive	8,0 %
	(80)	DiaMed	>>>	2 Positive	8,0 %
	(159)	Grifols	>>>	3 Positive	12 %
	(172)	Immucor	>>>	6 Positive	24 %
	(173)	Sanguin	>>>	4 Positive	16 %
	(174)	IVT Imuno	>>>	1 Positive	4,0 %
	(183)	Immunodiagnostic Systems	>>>	1 Positive	4,0 %
	(203)	ANTITOXIN	>>>	2 Positive	8,0 %
Total per sample: n = 25			Success: 100 %		
2	(6)	APR	>>>	1 Positive	4,0 %
	(14)	Bio-Rad	>>>	3 Positive	12 %
	(64)	Exbio Olomouc	>>>	2 Positive	8,0 %
	(80)	DiaMed	>>>	2 Positive	8,0 %
	(159)	Grifols	>>>	3 Positive	12 %
	(172)	Immucor	>>>	6 Positive	24 %
	(173)	Sanguin	>>>	4 Positive	16 %
	(174)	IVT Imuno	>>>	1 Positive	4,0 %
	(183)	Immunodiagnostic Systems	>>>	1 Positive	4,0 %
(203)	ANTITOXIN	>>>	2 Positive	8,0 %	
Total per sample: n = 25			Success: 100 %		
Total success: 100 %					

(1029) Antigen N

1	(6)	APR	>>>	1 Positive	4,3 %
	(14)	Bio-Rad	>>>	3 Positive	13 %
	(64)	Exbio Olomouc	>>>	2 Positive	8,7 %
	(80)	DiaMed	>>>	2 Positive	8,7 %
	(159)	Grifols	>>>	3 Positive	13 %
	(172)	Immucor	>>>	4 Positive	17 %
	(173)	Sanguin	>>>	4 Positive	17 %
	(174)	IVT Imuno	>>>	1 Positive	4,3 %
	(183)	Immunodiagnostic Systems	>>>	1 Positive	4,3 %
(203)	ANTITOXIN	>>>	2 Positive	8,7 %	
Total per sample: n = 23			Success: 100 %		
2	(6)	APR	>>>	1 Positive	4,3 %
	(14)	Bio-Rad	>>>	3 Positive	13 %
	(64)	Exbio Olomouc	>>>	2 Positive	8,7 %
	(80)	DiaMed	>>>	2 Positive	8,7 %
	(159)	Grifols	>>>	3 Positive	13 %
	(172)	Immucor	>>>	4 Positive	17 %
	(173)	Sanguin	>>>	4 Positive	17 %
	(174)	IVT Imuno	>>>	1 Positive	4,3 %
	(183)	Immunodiagnostic Systems	>>>	1 Positive	4,3 %
(203)	ANTITOXIN	>>>	2 Positive	8,7 %	
Total per sample: n = 23			Success: 100 %		
Total success: 100 %					

(1030) Antigen S

1	(6)	APR	>>>	1 Negative	3,8 %
	(14)	Bio-Rad	>>>	2 Negative	7,7 %
	(64)	Exbio Olomouc	>>>	1 Negative	3,8 %
	(80)	DiaMed	>>>	1 Positive	3,8 %
	(159)	Grifols	>>>	1 Negative	3,8 %
	(159)	Grifols	>>>	3 Negative	12 %
	(172)	Immucor	>>>	1 Positive	3,8 %
	(172)	Immucor	>>>	7 Negative	27 %
	(173)	Sanguin	>>>	1 Positive	3,8 %
	(173)	Sanguin	>>>	7 Negative	27 %
	(183)	Immunodiagnostic Systems	>>>	1 Negative	3,8 %
Total per sample: n = 26			Success: 88 %		
2	(6)	APR	>>>	1 Positive	3,8 %
	(14)	Bio-Rad	>>>	2 Positive	7,7 %
	(64)	Exbio Olomouc	>>>	2 Positive	7,7 %
	(80)	DiaMed	>>>	1 Positive	3,8 %
	(159)	Grifols	>>>	4 Positive	15 %
	(172)	Immucor	>>>	8 Positive	31 %
	(173)	Sanguin	>>>	7 Positive	27 %
(183)	Immunodiagnostic Systems	>>>	1 Positive	3,8 %	
Total per sample: n = 26			Success: 100 %		

Test					
Sample	Group		N	Result	N _{rel}
Total success: 88 %					
(1031) Antigen s					
1	(6) APR	>>>	1	Positive	5,3 %
	(14) Bio-Rad	>>>	1	Positive	5,3 %
	(64) Exbio Olomouc	>>>	2	Positive	11 %
	(80) DiaMed	>>>	1	Positive	5,3 %
	(159) Grifols	>>>	4	Positive	21 %
	(172) Immucor	>>>	10	Positive	53 %
Total per sample: n = 19		Success: 100 %			
2	(6) APR	>>>	1	Positive	5,3 %
	(14) Bio-Rad	>>>	1	Positive	5,3 %
	(64) Exbio Olomouc	>>>	2	Positive	11 %
	(80) DiaMed	>>>	1	Positive	5,3 %
	(159) Grifols	>>>	4	Positive	21 %
	(172) Immucor	>>>	10	Positive	53 %
Total per sample: n = 19		Success: 100 %			
Total success: 100 %					
(1032) Antigen P1					
1	(14) Bio-Rad	>>>	3	Negative	14 %
	(64) Exbio Olomouc	>>>	2	Negative	9,1 %
			1	Positive	4,5 %
	(80) DiaMed	>>>	2	Negative	9,1 %
	(159) Grifols	>>>	3	Negative	14 %
	(172) Immucor	>>>	5	Negative	23 %
	(173) Sanguin	>>>	6	Negative	27 %
Total per sample: n = 22		Success: 95 %			
2	(14) Bio-Rad	>>>	3	Positive	14 %
	(64) Exbio Olomouc	>>>	3	Positive	14 %
	(80) DiaMed	>>>	2	Positive	9,1 %
	(159) Grifols	>>>	3	Positive	14 %
	(172) Immucor	>>>	5	Positive	23 %
	(173) Sanguin	>>>	6	Positive	27 %
Total per sample: n = 22		Success: 100 %			
Total success: 95 %					
(1033) Antigen Jka					
1	(14) Bio-Rad	>>>	3	Positive	10 %
	(52) Dynex	>>>	2	Positive	6,9 %
	(64) Exbio Olomouc	>>>	3	Positive	10 %
	(159) Grifols	>>>	7	Positive	24 %
	(172) Immucor	>>>	6	Positive	21 %
	(173) Sanguin	>>>	8	Positive	28 %
Total per sample: n = 29		Success: 100 %			
2	(14) Bio-Rad		1	Not specified	3,4 %
		>>>	2	Positive	6,9 %
	(52) Dynex	>>>	2	Positive	6,9 %
	(64) Exbio Olomouc	>>>	3	Positive	10 %
	(159) Grifols	>>>	7	Positive	24 %
	(172) Immucor	>>>	6	Positive	21 %
	(173) Sanguin	>>>	8	Positive	28 %
Total per sample: n = 29		Success: 97 %			
Total success: 97 %					
(1034) Antigen Jkb					
1	(14) Bio-Rad	>>>	2	Positive	7,1 %
	(52) Dynex		1	Negative	3,6 %
	(64) Exbio Olomouc	>>>	3	Positive	11 %
	(159) Grifols	>>>	7	Positive	25 %
	(172) Immucor	>>>	6	Positive	21 %
	(173) Sanguin	>>>	9	Positive	32 %
Total per sample: n = 28		Success: 96 %			
2	(14) Bio-Rad	>>>	2	Positive	7,1 %
	(52) Dynex	>>>	1	Positive	3,6 %
	(64) Exbio Olomouc	>>>	3	Positive	11 %
	(159) Grifols	>>>	7	Positive	25 %
	(172) Immucor	>>>	6	Positive	21 %
	(173) Sanguin	>>>	9	Positive	32 %
Total per sample: n = 28		Success: 100 %			
Total success: 96 %					

Test					
Sample	Group		N	Result	N _{rel}
(1035) Antigen Lea					
1	(14) Bio-Rad	>>>	3	Negative	16 %
	(64) Exbio Olomouc	>>>	2	Negative	11 %
	(80) DiaMed	>>>	1	Negative	5,3 %
	(159) Grifols	>>>	3	Negative	16 %
	(172) Immucor	>>>	7	Negative	37 %
	(173) Sanguin	>>>	3	Negative	16 %
Total per sample: n = 19		Success: 100 %			
2	(14) Bio-Rad	>>>	3	Positive	16 %
	(64) Exbio Olomouc	>>>	2	Positive	11 %
	(80) DiaMed	>>>	1	Positive	5,3 %
	(159) Grifols	>>>	3	Positive	16 %
	(172) Immucor	>>>	7	Positive	37 %
	(173) Sanguin	>>>	3	Positive	16 %
Total per sample: n = 19		Success: 100 %			
Total success: 100 %					
(1036) Antigen Leb					
1	(14) Bio-Rad	>>>	3	Positive	16 %
	(64) Exbio Olomouc	>>>	2	Positive	11 %
	(80) DiaMed	>>>	1	Positive	5,3 %
	(159) Grifols	>>>	3	Positive	16 %
	(172) Immucor	>>>	7	Positive	37 %
	(173) Sanguin	>>>	3	Positive	16 %
Total per sample: n = 19		Success: 100 %			
2	(14) Bio-Rad	>>>	3	Negative	16 %
	(64) Exbio Olomouc	>>>	2	Negative	11 %
	(80) DiaMed	>>>	1	Negative	5,3 %
	(159) Grifols	>>>	2	Negative	11 %
	(172) Immucor	>>>	7	Negative	37 %
	(173) Sanguin	>>>	3	Negative	16 %
Total per sample: n = 19		Success: 95 %			
Total success: 95 %					